Synonymous mutations show no consistent prognostic role across cancers

Synonymous mutations—DNA changes that alter a codon without changing the encoded amino acid—have often been dismissed as neutral passengers in the cancer genome. A new pan-cancer analysis, published as an open-access research article in the Journal of Cancer Research and Clinical Oncology, tested whether mutations prioritized as potentially functional by a curated database actually carry clinical weight. The study, led by Tian-chi Ma, Fei Gao, Wen-heng Guo and colleagues with Wei Lin as senior author, was published on 28 October 2026 and analyzed data from 8136 patients spanning 18 cancer cohorts in The Cancer Genome Atlas.

The researchers did not treat all silent mutations equally. They applied three predefined functional-score thresholds from SynMICdb to prioritize synonymous mutations, then summarized the burden at the level of Cancer Gene Census genes. Associations with survival were evaluated using multivariable Cox models combined across cancer types through random-effects meta-analysis, with additional analyses adjusting for tumor stage and testing whether adding the synonymous-mutation burden improved prognostic models. Transcriptomic correlates were explored through gene-expression modeling and Hallmark pathway enrichment analysis.

The headline result is largely a negative one. Prioritized synonymous-mutation burden correlated only weakly with the broader nonsynonymous mutation burden, indicating that it captures something distinct rather than mirroring overall mutational load. Across the pan-cancer analysis, the team found no consistent association with overall survival or disease-specific survival. Modest associations with progression-related outcomes did emerge at the broader functional-score thresholds, but cancer-specific effects were heterogeneous, differing in direction and strength across tumor types.

A few cancer-specific signals survived stricter scrutiny. Associations with poorer overall survival in liver hepatocellular carcinoma and with disease-free interval in ovarian cancer persisted after adjustment for tumor stage. Even so, the incremental value for prognostic discrimination—how well models separate patients with different outcomes—remained limited. On the transcriptomic side, gene-expression profiles were highly concordant between the two broader thresholds, yet the linked pathway associations varied by cancer type, with no common transcriptional signature emerging across the panel.

The authors conclude that functionally prioritized synonymous mutations show heterogeneous, context-dependent clinical and transcriptional associations across cancer types. Selected cancer-specific associations, particularly those in liver hepatocellular carcinoma and ovarian cancer, may warrant further study. However, the absence of a consistent pan-cancer effect, combined with the limited improvement in prognostic performance, means the findings do not support using these mutations as a general prognostic tool in clinical practice. The study is openly accessible, and as an early-view article it remains subject to final editorial revision before the version of record appears.

Subject of Research: Clinical and transcriptomic associations of functionally prioritized synonymous mutations across 18 TCGA cancer cohorts

Article Title: Clinical associations of functionally prioritized synonymous mutations: a pan-cancer analysis

Article References: Ma, T.-C., Gao, F., Guo, W.-H., Liu, D.-M., Wang, H.-R., He, Y.-L., Yin, A.-A., & Lin, W. (2026). Clinical associations of functionally prioritized synonymous mutations: a pan-cancer analysis. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06648-w

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06648-w

Keywords: synonymous mutations, pan-cancer analysis, TCGA, prognosis, overall survival, disease-free interval, SynMICdb, Cancer Gene Census, Cox regression, meta-analysis, transcriptomics, hepatocellular carcinoma